Evaluation of the efficacy of haloperidol melitracen combined with betahistine in the treatment of anxiety depression type psychogenic dizziness
氟哌噻吨美利曲辛联合倍他司汀治疗焦虑-抑郁状态型心因性头晕患者的疗效评价

摘要

目的 探究氟哌噻吨美利曲辛联合倍他司汀治疗焦虑-抑郁状态型心因性头晕患者的临床效果。方法 选取我院2019年1月到2020年10月148例焦虑-抑郁状态型心因性头晕患者作为研究对象，采用电脑随机数字原则随机分为观察组、对照组，每组74例。对照组给予倍他司汀治疗，观察组给予氟哌噻吨美利曲辛联合倍他司汀治疗。比较两组治疗效果、汉密尔顿焦虑量表（HAMA）评分、汉密尔顿抑郁量表（HAMD）评分、生活质量综合评定量表（CQOLI-74）评分及不良反应发生情况。结果 治疗后，观察组总有效率95.95%明显高于对照组72.97%，差异具有统计学意义（P＜0.05）；治疗后，观察组HAMA、HAMD评分明显低于对照组，CQOLI-74评分明显高于对照组，差异具有统计学意义（P＜0.05）。结论 氟哌噻吨美利曲辛联合倍他司汀治疗焦虑-抑郁状态型心因性头晕患者效果显著，可明显缓解临床症状，提高生活质量，且不增加不良反应发生率。

Abstract

Objective: To explore the clinical effect of droperithiaton melitracen combined with betahistine in the treatment of anxiety depression type psychogenic dizziness.
Methods: 148 patients with psychogenic dizziness of anxiety depression type in our hospital from January 2019 to October 2020 were selected as the research objects. They were randomly divided into observation group and control group according to the principle of computer random number, with 74 cases in each group. The control group was treated with betahistine, and the observation group was treated with droperithiazide and melitracen combined with betahistine. The treatment effect, Hamilton Anxiety Scale (HAMA) score, Hamilton Depression Scale (HAMD) score, Comprehensive Quality of Life Rating Scale (CQOLI-74) score and adverse reactions were compared between the two groups.
Results: After treatment, the total effective rate of the observation group was 95.95%, which was significantly higher than that of the control group (72.97%, P<0.05); After treatment, the scores of HAMA and HAMD in the observation group were significantly lower than those in the control group, and the scores of CQOLI-74 were significantly higher than those in the control group (P<0.05).
Conclusion  : Flupentixol melitracen combined with betahistine is effective in the treatment of anxiety depression type psychogenic dizziness patients, which can significantly alleviate the clinical symptoms, improve the quality of life, and do not increase the incidence of adverse reactions.